← All trials
NCT06585540
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 13, 2024
- Primary completion
- Sep 30, 2025
- Completion date
- Jan 31, 2026
- First posted
- Sep 5, 2024
- Last posted
- Sep 26, 2024
- Enrollment
- 100
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Virginia Mason Medical CenterLead sponsor
- Virginia Mason Medical CenterCollaborator
- Virginia Mason Medical CenterOfficial
- Virginia Mason Medical CenterSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.